Data updated: Jun 28, 2026
Psoriatic Arthritis Clinical Trial Landscape
Psoriatic Arthritis is being studied across 185 clinical trials registered since 2008, with 50 programs currently active. The competitive pipeline includes 21 active Phase 3 trials, 12 active Phase 2 trials, and 6 active Phase 1 trials.
Top industry sponsors include UCB Biopharma SRL, AbbVie, Bristol-Myers Squibb.
Trial activity
50 active / 185 total since 2008
Active by phase 21 Ph3 / 80 12 Ph2 / 56 6 Ph1 / 19 11 Ph4 / 30
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
UCB Biopharma SRL 5 8 0
AbbVie 4 5 1
Bristol-Myers Squibb 3 3 0
Takeda 3 1 0
Amgen 2 10 0
Eli Lilly 2 5 0
Sun Pharmaceutical Industries Limited 2 3 0
Novartis 1 16 0
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 1 1 0
Spyre Therapeutics, Inc. 1 0 0
Merck 1 0 0
InventisBio Co., Ltd 1 0 0
CARE ARTHRITIS LTD. 1 0 0
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. 1 0 0
Seismic Therapeutic AU Pty Ltd 1 0 0
How the field has grown
New-trial starts peaked in 2019 (23 registered); 2025 saw 15. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (52 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 14
2017 14
2018 11
2019 23
2020 9
2021 11
2022 11
2023 8
2024 10
2025 15
2026 9
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (3) 186
2017 (9) 158
2018 (4) 243
2019 (9) 400
2020 (4) 339
2021 (5) 670
2022 (3) 351
2023 (3) 48
2024 (5) 200
2025 (6) 213
2026 (1) 1,182
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT06100744 RECRUITING
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
AbbVie n=40
NCT06624228 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
UCB Biopharma SRL n=684
NCT06506916 ACTIVE NOT RECRUITING
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
UCB Biopharma SRL n=89
NCT04908202 ACTIVE NOT RECRUITING
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
Bristol-Myers Squibb n=670
NCT04804553 RECRUITING
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
Amgen n=60
NCT06869551 RECRUITING
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
Bristol-Myers Squibb n=60
NCT06671483 RECRUITING
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Takeda n=1,088
NCT06671496 RECRUITING
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
Takeda n=600
NCT07295509 RECRUITING
A Study of Picankibart in Patients With Active Psoriatic Arthritis
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. n=222
NCT04527380 ACTIVE NOT RECRUITING
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Eli Lilly and Company n=101
NCT07286058 RECRUITING
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Takeda n=1,182
NCT04314531 ACTIVE NOT RECRUITING
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
Sun Pharmaceutical Industries Limited n=296
NCT04991116 ACTIVE NOT RECRUITING
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
Sun Pharmaceutical Industries Limited n=529
NCT06668181 RECRUITING
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
UCB Biopharma SRL n=40
NCT05767047 RECRUITING
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
Amgen n=48
NCT05669833 RECRUITING
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
University of Pennsylvania n=63
NCT07052214 RECRUITING
PSMA PET Combined With MRI for the Detection of PCa
Telix Pharmaceuticals (Innovations) Pty Limited n=204
NCT03671148 ACTIVE NOT RECRUITING
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
AbbVie n=444
NCT03675308 ACTIVE NOT RECRUITING
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
AbbVie n=964
NCT04908189 ACTIVE NOT RECRUITING
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
Bristol-Myers Squibb n=729
NCT06640257 RECRUITING
A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=200
NCT06588296 COMPLETED
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Eli Lilly and Company n=279
NCT04009499 COMPLETED
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
UCB Biopharma SRL n=1,131
NCT03370133 COMPLETED
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
UCB Biopharma SRL n=567
NCT03410992 COMPLETED
A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
UCB Biopharma SRL n=435
NCT03896581 COMPLETED
A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
UCB Biopharma SRL n=400
NCT03895203 COMPLETED
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
UCB Biopharma SRL n=852
NCT04314544 COMPLETED
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
Sun Pharmaceutical Industries Limited n=508
NCT01680159 COMPLETED
A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis
Tanabe Pharma Corporation n=51
NCT04108468 COMPLETED
GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA
The Leeds Teaching Hospitals NHS Trust n=84
NCT03769168 COMPLETED
An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
Novartis Pharmaceuticals n=55
NCT04632927 COMPLETED
Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment
Novartis Pharmaceuticals n=119
NCT03104400 COMPLETED
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
AbbVie n=1,705
NCT03104374 COMPLETED
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug
AbbVie n=642
NCT03598751 COMPLETED
Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis
Biocad n=194
NCT04209205 COMPLETED
Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
Novartis Pharmaceuticals n=381
NCT03103321 COMPLETED
Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer
Alliance for Clinical Trials in Oncology n=158
NCT03552276 COMPLETED
Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.
Sun Pharmaceutical Industries Limited n=281
NCT04711902 COMPLETED
Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.
Novartis Pharmaceuticals n=41
NCT03486457 COMPLETED
Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis
Pfizer n=204
NCT06084663 COMPLETED
Bioequivalence Study of Two Products of Apremilast 30 mg Tablets in Healthy, Adult, Human Subjects
Humanis Saglık Anonim Sirketi n=36
NCT04109976 COMPLETED
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis
UCB Biopharma SRL n=214
NCT05046431 COMPLETED
Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic Arthritis
Bio-Thera Solutions n=704
NCT02376790 COMPLETED
Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis
Amgen n=851
NCT03031782 COMPLETED
Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)
Novartis Pharmaceuticals n=86
NCT01307423 COMPLETED
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
Amgen n=529
NCT04115748 TERMINATED
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
Gilead Sciences n=67
NCT01860976 COMPLETED
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
Bristol-Myers Squibb n=489
NCT04115839 TERMINATED
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy
Gilead Sciences n=106
NCT01690299 COMPLETED
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
Amgen n=250
NCT03148860 COMPLETED
Impact of Concomitant MTX on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active PsA
Dr. Frank Behrens n=186
NCT02673151 COMPLETED
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
Andrei Iagaru n=61
NCT02662985 COMPLETED
Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)
Novartis Pharmaceuticals n=166
NCT02771210 COMPLETED
Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site
Novartis Pharmaceuticals n=204
NCT02745080 COMPLETED
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
Novartis Pharmaceuticals n=853
NCT02065713 COMPLETED
Efficacy of Golimumab in Combination With Methotrexate (MTX) Versus MTX Monotherapy, in Improving Dactylitis, in MTX naïve Psoriatic Arthritis Patients
Instituto de Medicina Molecular João Lobo Antunes n=44
NCT02024646 COMPLETED
Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis
Bausch Health Americas, Inc. n=484
NCT02349295 COMPLETED
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
Eli Lilly and Company n=363
NCT01172938 COMPLETED
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Amgen n=504
NCT01752634 COMPLETED
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
Novartis Pharmaceuticals n=397
NCT01925768 COMPLETED
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
Amgen n=219
NCT01212770 COMPLETED
PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Amgen n=505
NCT01212757 COMPLETED
PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Amgen n=488
NCT02404350 COMPLETED
Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis
Novartis Pharmaceuticals n=997
NCT02584855 COMPLETED
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
Eli Lilly and Company n=394
NCT03357471 COMPLETED
Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
UCB Biopharma S.P.R.L. n=70
NCT03736161 COMPLETED
Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis
Globe Pharmaceuticals Limited n=61
NCT01892436 COMPLETED
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
Novartis Pharmaceuticals n=460
NCT01989468 COMPLETED
24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis
Novartis Pharmaceuticals n=414
NCT01871649 COMPLETED
Initial Treatment With Golimumab in Early PsA
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) n=51
NCT01901185 COMPLETED
Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept
Amgen n=77
NCT01882439 COMPLETED
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
Pfizer n=395
NCT01877668 COMPLETED
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
Pfizer n=422
NCT02029495 TERMINATED
Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis
Bausch Health Americas, Inc. n=478
NCT01694264 TERMINATED
Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα
Seoul National University Hospital n=43
NCT01392326 COMPLETED
Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
Novartis Pharmaceuticals n=606
NCT02164214 COMPLETED
Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)?
Assistance Publique Hopitaux De Marseille n=60
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only